Schedules of Controlled Substances: Removal of 6-beta-Naltrexol from Control
2019-09-23 2019-09-23 2019-09-23 2019-09-23
DEA-2019-0007-0004 DEA-2019-0007-0005 DEA-2019-0007-0006 DEA-2019-0007-0007
04:00:00 04:00:00 04:00:00 04:00:00
https://api.regulations.gov/v4/comments/DEA-2019-0007-0004 https://api.regulations.gov/v4/comments/DEA-2019-0007-0005 https://api.regulations.gov/v4/comments/DEA-2019-0007-0006 https://api.regulations.gov/v4/comments/DEA-2019-0007-0007
Karan Anonymous Fil Phil
Kortlander Anonymous Lalau Hanzlik
Naltrexone is an opioid receptor antagonists and is commonly used in the treatment of opioid addiction and overdose, without the harmful addictive side effects of the drugs it treats.  Currently 6-Naltrexol is a schedule II controlled substance.  This proposed rule would allow more patients access to this life saving drug by removing the schedule II rating.  We agree with the action as it will save more lives and positively affect individuals and their families who struggle with drugs and alcohol addiction.Naltrexone is not a narcotic yet is used to help narcotic dependents who have stopped taking narcotics to stay drug-free. It is also used to help alcoholics stay alcohol-free. The medicine is not a cure for addiction. It is used as part of an overall program that may include counseling, attending support group meetings, and other treatment recommended by a health care provider. It will not produce any narcotic-like effects or cause mental or physical dependence however it may block the craving of wanting more. Naltrexone is prescribed for moderate-to-severe alcohol dependence, such as a patient that consumes five or more drink per day on a regular basis and has alcohol related problems. This medication is appropriate for patients that have tried to quit by abstaining from alcohol for several days before starting the medication. Naltrexone treatment is usually a minimum of 3 to 4 months. The goal is for the patient to be able to abstain from alcohol during this time, if so then treatment can be stopped. If on the other hand the patient continues to consume alcohol then the daily dose can be increased from 50 mg to 100 mg. There is also a monthly injection that is 380 mg and is given intramuscularly. Naltrexone is a drug that saves lives without the fear of addiction, and by removing this schedule II classification, it will become more available to a greater number of patients in need. 6 Beta Naltrexol, which is an opioid antagonist, meaning, it blocks the bodies receptors preventing the body from responding to endorphins and opioid. This drug should not be listed as a scheduled II substance as science has shown there are no known potentials for abuse in contrast to other schedule II drugs such as, morphine. On the other hand,  6 Beta Naltrexol has shown to work similarly to Naltrexone which was removed from all schedules effective in 1975 because of the lack of evidence to show the risk for abuse potential.  While, 6 Beta Naltrexol works like naltrexone it does differ in some aspects, for instance, it has a lower potency, a significantly long half life, and with higher plasma concentrations making it as effective as naltrexone when given by mouth. With the current number of deaths by overdose being 399,000 people from 1999-2017 involving opioids including prescription and illicit. It is imperative that new preventions including medications like 6 Beta Naltrexol be made available for treatment and provided to those at risk for overdose without the constraints of schedule II drugs. Centers for Disease Control  and Prevention. (2019). Drug overdose. Retrieved from https://www.cdc.gov/drugoverdose/data/statedeaths.html Its nuts that the majority of States have legalized the use of cannabis for recreational and medical use and the other States will make you a criminal and throw you in jail for years. Federal and States cannot accurately track tax revenues from cannabis sales because it is cash only transactions. And every day we get of cannabis is curing and helping people with their ailments from migraines and arthritis to pancreatic cancer (report from Harvard research: https://www.yahoo.com/lifestyle/study-on-cannabis-chemical-as-a-treatment-for-pancreatic-cancer-may-have-major-impact-harvard-researcher-says-165116708.html).Big Pharma has controlled the narrative with millions of dollars in political donations every year. Removing cannabis from being Schedule 1 drug is long over due and it is time to do whats best for America.Sincerely,Fil Lalau I just wanted to make sure that I understood this rule completely. My understanding of the proposed rule is that the DEA wants to declassify a drug that is only available in research labs, not available to the general public or to most physicians for prescription to patients, has no addictive properties, is not being used to for any purpose what so ever, and there is no history of any abuse of the drug, etc. I assume that there are plenty of other classified drugs that fall into the same category as this one. Why not spend more time worrying and combating drugs that are readily available to citizens or that are highly prescribed by physicians rather than wasting time on drugs that no one outside of a lab will ever see or ingest? For the record, I am for stronger drug laws in this country!!!